Boughey JC, Ballman KV, le-Petross HT, et al Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0 - T4, N1 - N2) who receive neoadjuvant chemotherapy: Results from ACOSOG
Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG
Z0011 Randomized Trial.
Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons.
Radiation field design in the ACOSOG Z0011 (Alliance) Trial.
After the negative results of the ESPAC-1 trial, neither the EORTC trial nor the ACOSOG study could further substantiate any benefit from the addition of radiation to chemotherapy.
ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon.
Based on this practice-changing trial result, guidelines of the National Comprehensive Cancer Network no longer recommend completion ALND for patients who meet the ACOSOG ZOO 11 criteria.
Ten-year survival results of ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1-2 NO M0 breast cancer who have a positive sentinel node (Alliance).
Although the ACOSOG
(American College of Surgeons Oncology Group) Z11 trial demonstrated that certain patients with limited SLN involvement were unlikely to benefit from completion of an ALND if the SLN was positive, none of the patients studied received neoadjuvant therapy.
The ACOSOG Z0011 trial (15) was a phase 3 trial conducted at 115 sites and involved examining women with clinical T1-T2 invasive breast cancer, no palpable adenopathy, and 1 to 2 SLNs containing metastasis identified by FS, permanent section, or touch preparation.
As described above, the results of the ACOSOG Z0011 clinical trial show that in patients with up to 2 positive SLNs there may not be added benefit with ALND.